{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Complete remission (CR): Bone marrow with \\</= 5% bone marrow blasts with normal maturation of all cell lines in the absence of extramedullary disease in addition to a peripheral blood granulocyte count \\>/= 1 X 10\\^9/L and a platelet count \\>/= 100 x 10\\^9 /L.","groups":[{"description":"Patients with morphological relapse for AML and MDS at least 90 days post-transplant.\n\nMDS patients: Re-appearance of dysplastic changes in the bone marrow, with or without increase in bone marrow blast count, which is pathologically consistent with myelodysplastic syndrome.\n\nAML patients:\n\nBone marrow blast count \\>/= 5%.","id":"OG000","title":"Cohort 1: Relapsed Leukemia Post-transplant"},{"description":"Cohort 2: Persistence or reappearance of minimal residual disease by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation.","id":"OG001","title":"Cohort 2: MRD(Minimal Residual Disease) Post-transplant"},{"description":"Cohort 3: High risk AML and MDS patients who are in complete remission morphologically with no evidence of minimal residual disease by flow cytometry or cytogenetic or molecular testing after allogeneic stem cell transplantation.","id":"OG002","title":"Cohort 3: Maintenance Treatment Post-transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within the first 6 cycles, up to 168 days.","title":"Number of Participants Achieved Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"Participants"}